BTAI Bioxcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.

$14.26  +1.06 (8.03%)
As of 07/01/2022 15:59:54 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/08/2018
Outstanding shares:  27,985,145
Average volume:  641,274
Market cap:   $369,403,914
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF4VBS8
Valuation   (See tab for details)
PE ratio:   -7.34
PB ratio:   2.06
PS ratio:   0.00
Return on equity:   -57.74%
Net income %:   -386,526.58%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy